Información del artículo
Resumen
La terapia biológica ha mostrado un efecto antipsoriásico muy satisfactorio; sin embargo, dicha respuesta no siempre se alcanza en todos los pacientes y además puede no resultar suficiente para otros. Por ello, recientemente se han diseñado estrategias entre las que destaca el uso de terapias combinadas con fármacos biológicos y sistémicos o la fototerapia. En este trabajo revisamos la terapia combinada con etanercept, fármacos sistémicos y fototerapia, y presentamos un paciente con psoriasis tratado con etanercept y UVB-BE.
Palabras clave:
Etanercept
Metotrexato
Ciclosporina
Acitretino
UVB-BE
PUVA
Terapia combinada
Abstract
Biological therapy has been shown to have a very satisfactory antipsoriasic effect. However, this response is not always achieved in all the patients and may be insufficient for others. Thus, strategies have recently been designed, among which the use of combined therapies with biological and systemic drugs or phototherapy have been designed. In this work, we have reviewed the combined therapy with etanercept, systemic drugs and phototherapy and present the case of a patient with psoriasis treated with etanercept and narrow band UVB.
Keywords:
Etanercept
Methotrexate
Cyclosporine
Acitretin
UV-B therapy
Psoralen-UV-A
Combination therapy
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. Ferrándiz, C. Bordas, V. García-Patos, S. Puig, R. Pujol, A. Smandia.
Prevalence of psoriasis in Spain (Epiderma Project: phase I).
J Eur Acad Dermatol Venereol, 15 (2001), pp. 20-23
[2.]
L. Puig, X. Bordas, J.M. Carrascosa, E. Daudén, C. Ferrándiz, J.M. Hernanz, et al.
Documento de consenso sobre evaluación y tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.
Actas Dermosifiliogr, 100 (2009), pp. 277-286
[3.]
L. Puig, J.M. Carrascosa, E. Daudén, J.L. Sánchez-Carazo, C. Ferrándiz, M. Sánchez-Regaña, Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología, et al.
Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos.
Actas Dermosifiliogr, 100 (2009), pp. 386-413
[4.]
D.M. Pariser, J. Bagel, J.M. Gelfand, N.J. Korman, C.T. Ritchlin, B.E. Strober, et al.
National Psoriasis Foundation, National Psoriasis Foundation clinical consensus on disease severity.
Arch Dermatol, 143 (2007), pp. 239-242
[5.]
W. Sterry, J. Barrer, W.H. Boehncke, J.D. Bos, S. Climenti, E. Christophers, et al.
Biological therapies in the systemic management of psoriasis: International Consensus Conference.
Br J Dermatol, 151 (2004), pp. 3-17
[6.]
A. Nast, M. Kopp, K.B. Augustin, W.H. Banditt, W.H. Boehncke, M. Follmann, et al.
German evidence-based guidelines for the treatment of psoriasis vulgaris (short version).
Arch Dermatol Res, 299 (2007), pp. 111-138
[7.]
R.G. Langley, V. Ho, C. Lynde, K.A. Papp, Y. Poulin, N. Shear, et al.
Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
J Cutan Med Surg, 9 (2006), pp. 18-25
[8.]
C.H. Smith, A.V. Anstey, J.N. Barrer, A.D. Burden, R.J. Chalmers, D. Chandler, British Association of Dermatologists, et al.
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.
Br J Dermatol, 153 (2005), pp. 486-497
[9.]
A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, K.B. Gordon, et al.
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
J Am Acad Dermatol, 58 (2008), pp. 826-850
[10.]
J.C. Cather, A. Menter.
Combining traditional agents and bio logics for the treatment of psoriasis.
Semin Cutan Med Surg, 24 (2005), pp. 37-45
[11.]
M. Lebwohl, S.B. Siskin, W. Epinette, D. Breneman, T. Funicella, R. Kalb, et al.
A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis.
J Am Acad Dermatol, 35 (1996), pp. 268-269
[12.]
M. Lebwohl.
Acitretin in combination with UVB or PUVA.
J Am Acad Dermatol, 41 (1999), pp. S22-S24
[13.]
S. Iyer, P. Yamauchi, N.J. Lowe.
Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy.
Br J Dermatol, 146 (2002), pp. 118-121
[14.]
J.M. Krell.
Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept.
J Am Acad Dermatol, 54 (2006), pp. 1099-1101
[15.]
G. Gupta, J. Long, D.M. Tillman.
The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures.
Br J Dermatol, 140 (1999), pp. 887-890
[16.]
G.D. Bandow, J.Y. Koo.
Narrow-band ultraviolet B radiation: a review of the current literature.
Int J Dermatol, 43 (2004), pp. 555-561
[17.]
S.S. Yones, R.A. Palmer, T.T. Garibaldinos, J.L. Hawk.
Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy.
Arch Dermatol, 142 (2006), pp. 836-842
[18.]
L. Kircik, J. Bagel, N. Korman, A. Menter, C.A. Elmets, J. Koo, et al.
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
J Drugs Dermatol, 7 (2008), pp. 245-253
[19.]
P. Wolf, A. Hofer, F.J. Legat, A. Bretterklieber, W. Weger, W. Salmhofer, et al.
Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept.
Br J Dermatol, 160 (2009), pp. 186-189
[20.]
W.G. Stebbins, M.G. Lebwohl.
Biologics in combination with non-biologics: efficacy and safety.
Dermatol Ther, 17 (2004), pp. 432-440
[21.]
A. Ortiz, P.S. Yamauchi.
A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents.
Skinmed, 5 (2006), pp. 285-288
[22.]
C. Ricotti, F.A. Kerdel.
Subacute annular generalized pustular psoriasis treated with etanercept and cyclosporine combination.
J Drugs Dermatol, 6 (2007), pp. 738-740
[23.]
U. Gül, M. Gönül, A. Kiliç, R. Erdem, S.K. Cakmak, H. Gündüz.
Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A.
Clin Ther, 28 (2006), pp. 251-254
[24.]
J. Conley, J. Nanton, S. Dhawan, D.J. Pearce, S.R. Feldman.
Novel combination regimens: biologics and acitretin for the treatment of psoriasis- a case series.
J Dermatolog Treat, 17 (2006), pp. 86-89
[25.]
E.C. Smith, C. Riddle, M.A. Menter, M. Lebwohl.
Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
Int J Dermatol, 47 (2008), pp. 514-518
[26.]
P. Gisondi, M. Del Giglio, C. Cotena, G. Girolomoni.
Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Br J Dermatol, 158 (2008), pp. 1345-1349
[27.]
S.G. Hodulik, J.A. Zeichner.
Combination therapy with acitretin for psoriasis.
J Dermatolog Treat, 17 (2006), pp. 108-111
[28.]
L. Klareskog, D. van der Heijde, J.P. de Jager, A. Gough, J. Kalden, M. Malaise, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators, et al.
Thera peutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
Lancet, 28 (2004), pp. 675-681
[29.]
P.L. Van Riel, A.J. Taggart, J. Sany, M. Gaubitz, H.W. Nab, R. Pedersen, Add Enbrel or Replace Methotrexate Study Investigators, et al.
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.
Ann Rheum Dis, 65 (2006), pp. 1478-1483
[30.]
P. Emery, F.C. Breedveld, S. Hall, P. Durez, D.J. Chang, D. Robertson, et al.
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
Lancet, 372 (2008), pp. 375-382
[31.]
P.S. Yamauchi, V. Gindi, N.J. Lowe.
The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety.
Dermatol Clin, 22 (2004), pp. 449-459
[32.]
P.S. Yamauchi, N.J. Lowe.
Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.
Int J Dermatol, 47 (2008), pp. 202-204
[33.]
C. Zachariae, N.J. Mørk, T. Reunala, H. Lorentzen, E. Falk, S.L. Karvonen, et al.
The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.
Acta Derm Venereol, 88 (2008), pp. 495-501
[34.]
B.E. Strober.
Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab.
Arch Dermatol, 140 (2004), pp. 366
[35.]
R.J.B. Driessen, P.C.M. van de Kerkhof, E.M.G.J. de Jong.
Etanercept combined with methotrexate for high-need psoriasis.
Br J Dermatol, 159 (2008), pp. 460-463
Copyright © 2010. Academia Española de Dermatología y Venereología
